The estimated Net Worth of Ronald B. Moss is at least $1.59 Milione dollars as of 18 March 2022. Ronald Moss owns over 8,199 units of Adamis Pharmaceuticals Corp stock worth over $155,471 and over the last 8 years he sold ADMP stock worth over $98,964. In addition, he makes $1,339,550 as Chief Medical Officer at Adamis Pharmaceuticals Corp.
Ronald has made over 12 trades of the Adamis Pharmaceuticals Corp stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 8,199 units of ADMP stock worth $4,919 on 18 March 2022.
The largest trade he's ever made was selling 35,553 units of Adamis Pharmaceuticals Corp stock on 1 December 2021 worth over $28,087. On average, Ronald trades about 8,217 units every 68 days since 2017. As of 18 March 2022 he still owns at least 201,911 units of Adamis Pharmaceuticals Corp stock.
You can see the complete history of Ronald Moss stock trades at the bottom of the page.
Dr. Ronald B. Moss M.D. serves as Chief Medical Officer of the Company. Dr. Moss joined the Company as Chief Medical Officer in February 2017. Prior to joining the Company, Dr. Moss served as President and Chief Executive Officer of Ansun Biopharma from October 2012 to February 2017 and as interim CEO from October 2011 to October 2012. Dr. Moss served as Executive Vice President of Clinical Development & Medical Affairs at NexBio from January 2009 to October 2011. From June 2006 to January 2009, Dr. Moss served as the Vice President of Clinical Development at Vical Inc. From January 2004 to March 2006, he served as the Vice President of Medical Affairs at Telos Pharmaceuticals. Dr. Moss served as the Senior Director of Worldwide Regulatory Affairs for Vaccines/Biologics at Merck and Company from January 2003 to January 2004. Dr. Moss joined The Immune Response Corporation in January 1994 as Medical Director and advanced through positions of increasing responsibility and served as the interim President and Chief Executive Officer from August 2002 to January 2003. From July 1993 to January 1994, Dr. Moss served as Assistant Medical Director at Immunization Products Ltd., a joint venture between Rhone-Poulenc Rorer and Immune Response. Dr. Moss trained in Pediatrics at SUNY Stony Brook and completed his Fellowship in Allergy and Clinical Immunology at the National Institutes of Health, and is board certified in allergy and immunology. He is a Fellow of the American Academy of Allergy, Asthma and Immunology (FAAAAI) and a Fellow of the American College of Allergy, Asthma, and Immunology (FACAAI). Dr. Moss is a voluntary associate clinical professor at University of California, San Diego, School of Medicine Department of Medicine. Dr. Moss earned his M.D. degree at the Chicago Medical School, Rosalind Franklin University of Medicine and Science and his bachelor’s degree from the State University of New York at Stony Brook.
As the Chief Medical Officer of Adamis Pharmaceuticals Corp, the total compensation of Ronald Moss at Adamis Pharmaceuticals Corp is $1,339,550. There are 1 executives at Adamis Pharmaceuticals Corp getting paid more, with Dennis Carlo having the highest compensation of $1,770,310.
Ronald Moss is 60, he's been the Chief Medical Officer of Adamis Pharmaceuticals Corp since 2017. There are 8 older and 3 younger executives at Adamis Pharmaceuticals Corp. The oldest executive at Adamis Pharmaceuticals Corp is Dr. Dennis J. Carlo, 78, who is the Pres, CEO & Director.
Ronald's mailing address filed with the SEC is C/O ADAMIS PHARMACEUTICALS CORPORATION, 11682 EL CAMINO REAL, STE 300, SAN DIEGO, CA, 92130.
Over the last 14 years, insiders at Adamis Pharmaceuticals Corp have traded over $2,051,720 worth of Adamis Pharmaceuticals Corp stock and bought 87,550 units worth $188,843 . The most active insiders traders include Ahmed Shayan Fazlur Eses Ho..., Dennis J Phd Carlo e David J. Marguglio. On average, Adamis Pharmaceuticals Corp executives and independent directors trade stock every 34 days with the average trade being worth of $12,919. The most recent stock trade was executed by Dennis J Phd Carlo on 25 May 2022, trading 250,000 units of ADMP stock currently worth $192,500.
adamis pharmaceuticals corporation (nasdaq: admp) is a specialty biopharmaceuticals company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergies, oncology and immunology. its specialty pharmaceutical division currently has four products in its pipeline including the epinephrine injection pre-filled syringe (pfs) for use in the emergency treatment of anaphylaxis, apc-1000 and apc-5000 (dry powder inhaler) for the treatment of asthma and chronic obstructive pulmonary disease (copd), and apc-3000, a hydrofluoroalkane (hfa) inhaled nasal steroid product for the treatment of allergic rhinitis. this division’s focus is to create low cost therapeutic alternatives to existing treatments in large markets. adamis will pursue 505(b)(2) regulatory approval filings in order to minimize costs and shorten the time to market in this division. within its biotechnology division, the company has four products under development include telob-vax, a
Adamis Pharmaceuticals Corp executives and other stock owners filed with the SEC include: